Oxaliplatin–Biomimetic Magnetic Nanoparticle Assemblies for Colon Cancer-Targeted Chemotherapy: An In Vitro Study
Metadatos
Mostrar el registro completo del ítemAutor
Jabalera Ruz, Ylenia María; García Pinel, Beatriz; Ortiz, Raúl; Iglesias Salto, Guillermo Ramón; Cabeza, Laura; Prados Salazar, José Carlos; Jiménez López, Concepción; Melguizo Alonso, ConsolaciónEditorial
MDPI
Materia
Colon carcinoma Magnetite nanoparticles Magnetotactic bacteria Oxaliplatin Nanocarriers
Fecha
2019-08-06Referencia bibliográfica
Jabalera, Y., Garcia-Pinel, B., Ortiz, R., Iglesias, G., Cabeza, L., Prados, J., ... & Melguizo, C. (2019). Oxaliplatin–Biomimetic Magnetic Nanoparticle Assemblies for Colon Cancer-Targeted Chemotherapy: An In Vitro Study. Pharmaceutics, 11(8), 395.
Patrocinador
This work was also supported by the Consejería de Salud de la Junta de Andalucía (projects PI-0476-2016 and PI-0102-2017). Y.J. and B.G.-P. acknowledge FPU2016 grants (FPU16_04580 and FPU16_01716, respectively) from the Ministerio de Educación, Ciencia, y Deporte y Competitividad (Spain).Resumen
Conventional chemotherapy against colorectal cancer (CRC), the third most common cancer
in the world, includes oxaliplatin (Oxa) which induces serious unwanted side effects that limit the
efficiency of treatment. Therefore, alternative therapeutic approaches are urgently required. In this
work, biomimetic magnetic nanoparticles (BMNPs) mediated by MamC were coupled to Oxa to
evaluate the potential of the Oxa–BMNP nanoassembly for directed local delivery of the drug as a
proof of concept for the future development of targeted chemotherapy against CRC. Electrostatic
interactions between Oxa and BMNPs trigger the formation of the nanoassembly and keep it stable at
physiological pH. When the BMNPs become neutral at acidic pH values, the Oxa is released, and such
a release is greatly potentiated by hyperthermia. The coupling of the drug with the BMNPs improves
its toxicity to even higher levels than the soluble drug, probably because of the fast internalization of
the nanoassembly by tumor cells through endocytosis. In addition, the BMNPs are cytocompatible
and non-hemolytic, providing positive feedback as a proof of concept for the nanoassembly. Our
study clearly demonstrates the applicability of Oxa–BMNP in colon cancer and offers a promising
nanoassembly for targeted chemotherapy against this type of tumor.